Evommune (EVMN) Operating Income Growth (1y) (2025 - 2026)

Evommune (EVMN) Operating Income Growth (1y) (2025 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 66,561.01 Bn 66,560.72 Bn - -24.89%
2 Nanobiotix 1,911.11 Bn 1,911.05 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - -
4 BeOne Medicines 467.81 Bn 463.02 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 122.92 Bn 115.68 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 70.28 Bn 61.53 Bn 3.31 Bn 8.65%
7 Belite Bio 62.88 Bn 62.88 Bn - -
8 Argenx Se 55.90 Bn 50.72 Bn 1.41 Bn 145.20%
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn 1,386.07%
10 Evommune 385.52 Mn 174.06 Mn - -59.35%

Historic Data

Download Data
DateValue
Mar 31, 2026 -59.35%
Dec 31, 2025 -38.51%
Sep 30, 2025 19.31%